{"id":"idp-126-vehicle-gel","safety":{"commonSideEffects":[]},"_chembl":null,"_fixedAt":"2026-03-30T13:32:34.001423","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IDP-126 Vehicle Gel is a phase 3 topical formulation developed by Bausch Health Americas. As a vehicle gel, it serves as the delivery system for active ingredients in dermatological applications. The specific mechanism depends on the active pharmaceutical ingredient incorporated into the gel matrix.","oneSentence":"IDP-126 is a topical gel formulation designed to deliver active pharmaceutical ingredients to treat dermatological conditions.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:15:31.157Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dermatological conditions (specific indication not publicly disclosed)"}]},"_fixedFields":["pubmed(3)"],"trialDetails":[{"nctId":"NCT04892706","phase":"PHASE2","title":"Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2021-06-11","conditions":"Acne Vulgaris","enrollment":686},{"nctId":"NCT04214652","phase":"PHASE3","title":"Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2020-01-27","conditions":"Acne Vulgaris","enrollment":180},{"nctId":"NCT04214639","phase":"PHASE3","title":"Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2020-01-17","conditions":"Acne Vulgaris","enrollment":183},{"nctId":"NCT03170388","phase":"PHASE2","title":"A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2017-10-05","conditions":"Acne Vulgaris","enrollment":741}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"recentPublications":[{"date":"2024","pmid":"39433524","title":"CABTREO(TM) (Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide) Topical Gel.","journal":"Skinmed"},{"date":"2023 Nov","pmid":"37656094","title":"Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for moderate-to-severe acne: Efficacy and safety results from two randomized phase 3 trials.","journal":"Journal of the American Academy of Dermatology"},{"date":"2023 May-Jun","pmid":"36949579","title":"Triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel for moderate-to-severe acne in children and adolescents: Randomized phase 2 study.","journal":"Pediatric dermatology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vehicle"],"phase":"phase_3","status":"active","brandName":"IDP-126 Vehicle Gel","genericName":"IDP-126 Vehicle Gel","companyName":"Bausch Health Americas, Inc.","companyId":"bausch-health-americas-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IDP-126 is a topical gel formulation designed to deliver active pharmaceutical ingredients to treat dermatological conditions. Used for Dermatological conditions (specific indication not publicly disclosed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}